You are here

BCRF Grantee Since


Donor Recognition

The Play for P.I.N.K. Award

Area(s) of Focus

John M.S. Bartlett, PhD

Director, Transformative Pathology Platform and the Ontario Tumor Bank
Ontario Institute for Cancer Research
Honorary Professor, The University of Edinburgh
Toronto, Ontario, Canada

Current Research

Male Breast Cancer (BC) is a rare disease accounting for less than 1% of all BC. Knowledge about male BC is scarce, and treatment and management is based on female BC. To better characterize this disease and ultimately develop specific treatments and improve outcomes for men with BC, the Male Breast Cancer International Program was created. Dr. Bartlett is part of a team of BCRF grantees participating in this worldwide effort coordinated by the European Organization for the Research and Treatment of Cancer (EORTC), with the help of the Translational Breast Cancer Research Consortium (TBCRC), and run under the network of the Breast International Group (BIG) and the North American Breast Cancer Groups (NABCG). This Program has three parts. Part One is analyzing over 1600 male BC cases treated in the last 20 years to better understand the biology of the disease. This is the largest series of male BC cases ever studied and early results will be presented at the San Antonio Breast Cancer Symposium in 2014. Part Two of the study is focused on creating a registry of all male breast cancer patients treated within the EORTC/TBCRC/BIG/NABCG global network and includes collection of biological material that can be used for future studies. Part Three is a prospective clinical trial that will evaluate a new drug to treat male breast cancer. This program, which includes 23 centers in 9 countries, can exist only due to the continuous and crucial support from BCRF and will lead to the development of better treatment strategies for male breast cancer.


Professor John Bartlett is Professor of Molecular Pathology at Edinburgh University, Fellow of the Royal College of Pathologists and the Group Leader of the Endocrine Cancer Group at the University of Edinburgh Cancer Research Centre at the Western General Hospital Dr Bartlett graduated in 1982 with a B.Sc (hons) in Biochemistry and subsequently a PhD in reproductive physiology in 1985. His interest in cancer research and molecular biology started in 1990 and he joined the University of Edinburgh in March 2006. Over the past 10 years he has developed research into the molecular biology of breast cancer during which time he has developed a significant expertise in translational science in breast cancer and the pathobiology of type I receptor tyrosine kinases. He is the author of over 125 papers. Dr John Bartlett is also involved in the TRANSBIG research network and in scientific working groups as part of the Breast International Group (BIG) network.